Exicure, Inc. (NASDAQ:XCUR) Sees Large Decline in Short Interest

Exicure, Inc. (NASDAQ:XCUR) saw a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 22,700 shares, a decline of 16.2% from the January 31st total of 27,100 shares. Currently, 6.0% of the company’s shares are short sold. Based on an average daily trading volume, of 600,700 shares, the short-interest ratio is presently 0.0 days.

Hedge Funds Weigh In On Exicure

A hedge fund recently bought a new stake in Exicure stock. Geode Capital Management LLC acquired a new position in shares of Exicure, Inc. (NASDAQ:XCUR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned about 0.48% of Exicure as of its most recent filing with the Securities and Exchange Commission (SEC). 42.82% of the stock is owned by institutional investors.

Exicure Stock Performance

NASDAQ XCUR opened at $9.95 on Thursday. The stock’s fifty day moving average is $10.81 and its two-hundred day moving average is $8.63. The firm has a market capitalization of $25.93 million, a P/E ratio of -4.81 and a beta of 3.76. Exicure has a fifty-two week low of $1.44 and a fifty-two week high of $36.00.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.